Aclarion's NOCISCAN enables noninvasive identification of discogenic pain using MR Spectroscopy and AI, presented by Dr. Berven.
Quiver AI Summary
Aclarion, Inc. is set to showcase its advanced platform, NOCISCAN, at the Selby Spine Conference, presented by Dr. Sigurd Berven. NOCISCAN combines MR Spectroscopy and augmented intelligence to noninvasively identify the source of chronic low back pain, particularly distinguishing between painful and nonpainful discs. Ryan Bond, Aclarion's Chief Strategy Officer, noted the importance of NOCISCAN in enabling physicians to enhance treatment personalization for chronic low back pain patients by revealing what traditional imaging cannot. The platform, the first of its kind supported by evidence, aims to revolutionize chronic pain management and spine surgery by providing clear insights into pain location through chemical biomarker analysis. The presentation is scheduled for January 31, 2025, in Deer Valley, Utah.
Potential Positives
- Aclarion’s participation in the prestigious Selby Spine Conference highlights its commitment to innovation in healthcare technology, particularly in chronic low back pain management.
- The presentation by Dr. Sigurd Berven emphasizes the advanced capabilities of NOCISCAN, positioning it as a new gold standard in noninvasive diagnostics.
- NOCISCAN is the first evidence-supported SaaS platform specifically designed to distinguish between painful and nonpainful discs, addressing a critical need in the global healthcare market.
- The technology combines MR Spectroscopy with augmented intelligence, potentially leading to more effective treatment strategies for millions affected by chronic low back pain.
Potential Negatives
- Overemphasis on innovative capabilities without providing concrete clinical outcomes or data may raise skepticism among healthcare professionals regarding the effectiveness of NOCISCAN.
- Reliance on forward-looking statements raises concerns about the company's transparency and may lead to investor distrust, especially if future results do not meet expectations.
- The potential for technological adoption issues or resistance from healthcare providers who are accustomed to traditional imaging techniques could hinder the widespread acceptance of NOCISCAN.
FAQ
What is NOCISCAN?
NOCISCAN is Aclarion's flagship platform that combines MR Spectroscopy and augmented intelligence to identify sources of chronic low back pain noninvasively.
Who is presenting at the Selby Spine Conference?
Dr. Sigurd Berven, a renowned spine specialist, will present Aclarion's NOCISCAN capabilities at the Selby Spine Conference.
How does NOCISCAN improve chronic pain diagnosis?
NOCISCAN uses biomarkers and proprietary algorithms to distinguish painful from non-painful discs, enhancing diagnosis beyond traditional imaging methods.
When and where will Dr. Berven's presentation occur?
Dr. Berven's presentation is scheduled for January 31, 2025, at 5:55 PM, during the Selby Spine Conference in Deer Valley, UT.
What is the significance of the Selby Spine Conference?
The Selby Spine Conference is an important venue for medical professionals to learn about innovations in spine treatment and pain management, including NOCISCAN.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACON Hedge Fund Activity
We have seen 5 institutional investors add shares of $ACON stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPTRUST FINANCIAL ADVISORS added 50,000 shares (+30.5%) to their portfolio in Q3 2024, for an estimated $9,170
- CITADEL ADVISORS LLC removed 28,839 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,289
- TWO SIGMA SECURITIES, LLC added 17,205 shares (+53.6%) to their portfolio in Q3 2024, for an estimated $3,155
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 14,153 shares (+inf%) to their portfolio in Q3 2024, for an estimated $2,595
- GROUND SWELL CAPITAL, LLC removed 12,947 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,374
- JANE STREET GROUP, LLC added 12,239 shares (+inf%) to their portfolio in Q3 2024, for an estimated $2,244
- GEODE CAPITAL MANAGEMENT, LLC removed 8,172 shares (-19.4%) from their portfolio in Q3 2024, for an estimated $1,498
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI)
- NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain
BROOMFIELD, Colo., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference. Renowned spine specialist, Dr. Sigurd Berven , will present Aclarion's flagship platform, NOCISCAN , highlighting its innovative, evidence-supported capabilities.
“Aclarion is pleased to have NOCISCAN featured at the Shelby Spine Conference,” said Ryan Bond, Chief Strategy Officer. “We are honored to have renowned physicians like Dr. Berven illustrate how utilizing NOCISCAN can help physicians identify what they can’t ‘see’ with traditional imaging so they can personalize treatment for patients with chronic low back pain.”
Dr. Berven's presentation, titled "MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard," will delve into how NOCISCAN empowers physicians to noninvasively identify biomarkers that are invisible on traditional MRI scans. This breakthrough enables tailored, data-driven treatment plans for chronic low back pain patients.
Details of the Presentation:
- Date: Friday, January 31, 2025
- Time: 5:55 PM
-
Location:
Selby Spine Conference, Deer Valley, UT
NOCISCAN is revolutionizing spine surgery and chronic pain management by combining cutting-edge MR Spectroscopy with augmented intelligence, setting a new standard for noninvasive diagnostics.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s NOCISCAN solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. NOCISCAN objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain.
For a copy of the NOCISCAN presentation, please email: [email protected]
To find a NOCISCAN center, view our site map here .
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
[email protected]
Media Contact:
Jennie Kim
SPRIG Consulting
[email protected]